Literature DB >> 3782422

Differences in the interaction between dopamine and estradiol on prolactin release by cultured normal and tumorous human pituitary cells.

S W Lamberts, T Verleun, L Hofland, R Oosterom.   

Abstract

We studied the interaction between dopamine and estradiol on PRL release by cultured normal and tumorous PRL-secreting cells prepared from human pituitaries. If pituitary glands were obtained within 3 h after sudden death of previously normal individuals, the viability of isolated pituitary cells prepared by dispersion with dispase was more than 75%. After 4 days of culture, dopamine (500 nM) inhibited PRL release by cells prepared from four normal pituitaries by 24 +/- 3% (+/- SEM). Pretreatment of the cells with 100 nM estradiol did not alter dopamine-mediated inhibition of PRL release. Estradiol alone increased basal PRL release and cell PRL content. Cultured PRL-secreting pituitary tumor cells, obtained by transsphenoidal operation from four patients, were similarly sensitive to dopamine. Estradiol stimulated tumor cell PRL release and content, but significantly diminished the inhibitory effect of dopamine. The estrogen receptor blocker tamoxifen did not alter PRL release, but it did reverse the estradiol-induced insensitivity of the prolactinoma cells to the dopamine agonist bromocriptine. In conclusion, these in vitro results indicate that estrogens do not antagonize the effect of dopamine on normal human PRL-secreting pituitary cells. In human pituitary tumor cells, however, estradiol decreased the sensitivity of PRL release to dopamine (agonists), and the estrogen action can be acutely reversed by tamoxifen.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3782422     DOI: 10.1210/jcem-63-6-1342

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  7 in total

Review 1.  Pharmacologic resistance in prolactinoma patients.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2005       Impact factor: 4.107

Review 2.  Control of prolactin secretion.

Authors:  G Benker; C Jaspers; G Häusler; D Reinwein
Journal:  Klin Wochenschr       Date:  1990-12-04

3.  Temozolomide in the treatment of an invasive prolactinoma resistant to dopamine agonists.

Authors:  Lisa M Neff; Michelle Weil; Alan Cole; Thomas R Hedges; William Shucart; Donald Lawrence; Jay-Jiguang Zhu; Arthur S Tischler; Ronald M Lechan
Journal:  Pituitary       Date:  2007       Impact factor: 4.107

Review 4.  Dopamine resistance of prolactinomas.

Authors:  Mark E Molitch
Journal:  Pituitary       Date:  2003       Impact factor: 4.107

5.  Expression of D2RmRNA isoforms and ERmRNA isoforms in prolactinomas: correlation with the response to bromocriptine and with tumor biological behavior.

Authors:  Zhe Bao Wu; Wei Ming Zheng; Zhi Peng Su; Yong Chen; Jin Sen Wu; Cheng De Wang; Chen Lin; Yan Jun Zeng; Qi Chuan Zhuge
Journal:  J Neurooncol       Date:  2010-01-09       Impact factor: 4.130

Review 6.  Management of medically refractory prolactinoma.

Authors:  Mark E Molitch
Journal:  J Neurooncol       Date:  2013-10-22       Impact factor: 4.130

Review 7.  What can we learn from rodents about prolactin in humans?

Authors:  Nira Ben-Jonathan; Christopher R LaPensee; Elizabeth W LaPensee
Journal:  Endocr Rev       Date:  2007-12-05       Impact factor: 19.871

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.